Verastem, Inc. $VSTM

What the company doesAI summary of filing

Verastem is a biopharmaceutical company developing and commercializing medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK (avutometinib plus defactinib), which received FDA accelerated approval in May 2025 for adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, and generated $30.9 million in net product revenue during its first seven months of commercialization. The company is also conducting a Phase 3 confirmatory trial (RAMP 301) for this combination and is advancing clinical-stage programs including VS-7375, a KRAS G12D inhibitor in Phase 1/2 development for pancreatic, lung, and colorectal cancers, along with preclinical programs targeting RAS/MAPK pathway-driven cancers. [10-K 2026-03-04]

Segments: AVMAPKI FAKZYNJA CO-PACK (avutometinib + defactinib), Avutometinib + defactinib in pancreatic cancer (RAMP 205), VS-7375 (KRAS G12D inhibitor), Preclinical programs (undisclosed assets from GenFleet collaboration)